Clinical Trial Update: Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures [NA]

View source ↗

Summary

A clinical trial is investigating personalized first-line chemotherapy choices for advanced pancreatic ductal adenocarcinoma using tumor transcriptomic signatur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Institut Curie | Conditions: Carcinoma, Pancreatic Ductal, Prognosis | NA | Status: RECRUITING